These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 30824817)
1. A pathway-driven predictive model of tramadol pharmacogenetics. Wendt FR; Novroski NMM; Rahikainen AL; Sajantila A; Budowle B Eur J Hum Genet; 2019 Jul; 27(7):1143-1156. PubMed ID: 30824817 [TBL] [Abstract][Full Text] [Related]
2. Predicted activity of UGT2B7, ABCB1, OPRM1, and COMT using full-gene haplotypes and their association with the CYP2D6-inferred metabolizer phenotype. Wendt FR; Sajantila A; Budowle B Forensic Sci Int Genet; 2018 Mar; 33():48-58. PubMed ID: 29190510 [TBL] [Abstract][Full Text] [Related]
3. Supervised Classification of CYP2D6 Genotype and Metabolizer Phenotype With Postmortem Tramadol-Exposed Finns. Wendt FR; Novroski NMM; Rahikainen AL; Sajantila A; Budowle B Am J Forensic Med Pathol; 2019 Mar; 40(1):8-18. PubMed ID: 30507617 [TBL] [Abstract][Full Text] [Related]
4. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics. Saiz-Rodríguez M; Ochoa D; Román M; Zubiaur P; Koller D; Mejía G; Abad-Santos F Pharmacogenomics; 2020 Jul; 21(10):663-675. PubMed ID: 32538291 [TBL] [Abstract][Full Text] [Related]
5. Global genetic variation of select opiate metabolism genes in self-reported healthy individuals. Wendt FR; Pathak G; Sajantila A; Chakraborty R; Budowle B Pharmacogenomics J; 2018 Apr; 18(2):281-294. PubMed ID: 28398354 [TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367 [TBL] [Abstract][Full Text] [Related]
7. A logistic equation to determine the validity of tramadol from related gene polymorphisms and psychological factors. Zhao Q; Sun J; Tao Y; Wang S; Jiang C; Zhu Y; Yu F; Zhu J Pharmacogenomics; 2014 Mar; 15(4):487-95. PubMed ID: 24624916 [TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose. Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712 [TBL] [Abstract][Full Text] [Related]
9. Analgesia and Opioids: A Pharmacogenetics Shortlist for Implementation in Clinical Practice. Matic M; de Wildt SN; Tibboel D; van Schaik RHN Clin Chem; 2017 Jul; 63(7):1204-1213. PubMed ID: 28637770 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics and Morphine. Ofoegbu A; B Ettienne E J Clin Pharmacol; 2021 Sep; 61(9):1149-1155. PubMed ID: 33847389 [TBL] [Abstract][Full Text] [Related]
11. The Pharmacogenetics of Tramadol. Lassen D; Damkier P; Brøsen K Clin Pharmacokinet; 2015 Aug; 54(8):825-36. PubMed ID: 25910878 [TBL] [Abstract][Full Text] [Related]
13. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Levo A; Koski A; Ojanperä I; Vuori E; Sajantila A Forensic Sci Int; 2003 Jul; 135(1):9-15. PubMed ID: 12893130 [TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacogenetics and potential application in personalized medicine. Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611 [TBL] [Abstract][Full Text] [Related]
15. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms. Ruano G; Kost JA Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992 [TBL] [Abstract][Full Text] [Related]
16. Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants. Allegaert K; van Schaik RH; Vermeersch S; Verbesselt R; Cossey V; Vanhole C; van Fessem M; de Hoon J; van den Anker JN Pediatr Res; 2008 Jun; 63(6):674-9. PubMed ID: 18317231 [TBL] [Abstract][Full Text] [Related]
17. Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects. Saiz-Rodríguez M; Ochoa D; Herrador C; Belmonte C; Román M; Alday E; Koller D; Zubiaur P; Mejía G; Hernández-Martínez M; Abad-Santos F Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):321-329. PubMed ID: 30281924 [TBL] [Abstract][Full Text] [Related]
18. Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. Joly P; Gagnieu MC; Bardel C; Francina A; Pondarre C; Martin C Am J Hematol; 2012 May; 87(5):534-6. PubMed ID: 22430884 [TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225 [TBL] [Abstract][Full Text] [Related]
20. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics. Zahari Z; Ismail R Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]